Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Christopher KennardEmeritus Professor of Clinical Neurology, Professor Christopher Kennard joins the Medical Sciences Division as its new interim Head of Division today, replacing Professor Alastair Buchan, who will be taking a new role as the University’s Head of Brexit Strategy. Professor Kennard knows the Division well, having served, until his retirement late last year, as the Head of the Nuffield Department of Clinical Neuroscience, one of the 16 departments within the Division. Prior to his arrival in Oxford, Prof Kennard was the Deputy Principal for the Faculty of Medicine at Imperial College, London.

Professor Christopher Kennard commented:  “It is a great honour to have been invited by the VC to take on the role of interim Head of the Medical Sciences Division, following Alastair Buchan’s move to become the Head of Brexit Strategy for the University. During his nine year tenure he successfully led the Division to its premier international position and made major contributions in many areas. I very much look forward to being able to contribute to the Division’s continuing success and to work with such an exceptionally talented group of teachers and researchers.”

Professor Louise Richardson, Vice-Chancellor, said: “I am deeply grateful to Professor Christopher Kennard for agreeing to assume the role of Head of Division on an interim basis until a new Head of Division is appointed. The Division sought Council’s approval for the process of selecting a new Head of Division, and we expect to have a new head in place before Professor Alastair Buchan’s term would ordinarily have concluded.”

Similar stories

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.